Latest / The Nerve – It’s a Pain in the Face / Exploring Your Options: Could a Clinical Trial be Right for You?
Transcript
- 0:00Music.
- 0:10Welcome to The Nerve. It's a pain in the face, a podcast dedicated to covering
- 0:15all topics relevant to neuropathic facial pain.
- 0:18Hosted by the Facial Pain Association, our mission is to provide a platform
- 0:22that informs, empowers, and connects individuals within the facial pain community.
- 0:28Whether you are a person living with facial pain, a caregiver,
- 0:32or a healthcare professional, we are glad you are here to join us as we delve
- 0:37into the world of neuropathic facial pain.
- 0:40Trigeminal neuralgia is a complex condition, but as we learned in our recent
- 0:45webinar to wrap up Facial Pain Awareness Month in October, there are advances
- 0:49in care, offering new hope to patients.
- 0:52My name is Brandi Underwood, and I serve as the Manager of Development,
- 0:56Research, and Advocacy for the Facial Pain Association.
- 1:00Joining me today are four experts from Noema Pharma who are leading this effort.
- 1:05It is my honor to introduce Dr.
- 1:08Rob Lasser, currently the Chief Medical Officer at Noema Pharma.
- 1:12He is an adult and geriatric psychiatrist with over 25 years of experience in
- 1:18developing new medications for psychiatric and neurologic illnesses.
- 1:23Next, we have Amin Tahiri, Vice President, Medical and Development Strategy at Noema Pharma.
- 1:30He is a PharmD based in Europe and in the last 10 years has developed drugs
- 1:34to address neurological conditions.
- 1:37Joining us next, we have Rob Silva, Vice President of Clinical Science at Nuima Pharma.
- 1:43Rob holds a Ph.D. in neuroscience and has over 23 years in the pharmaceutical
- 1:48industry as a clinical researcher with expertise in neurology and psychiatry.
- 1:54Last but not least, Denise Bedoya, Director of Clinical Operations at Nuima Pharma, joins us.
- 2:01Denise is a seasoned research professional with over 25 years of extensive experience
- 2:06in clinical operations and development across all phases of research,
- 2:11epidemiology, and longitudinal trials.
- 2:14Welcome, everyone. It's great to have you here with us today.
- 2:18In the webinar a few weeks ago, we explored the Libra study in great detail.
- 2:23Dr. Lasser, can you give those listening to today's podcast a brief overview of the trial?
- 2:29Of course. I'd first love to first thank you for your kind introduction and
- 2:34certainly welcome all the podcast listeners.
- 2:37As Brandy mentioned, at Noemo, we've been leading a study examining trigeminal
- 2:42neuralgia, an investigational medication called NOE-101 or bisimglurant,
- 2:48for the past several years.
- 2:50Patients just like you and the FPA have been super in helping us collaboratively achieve our goals.
- 2:57So I'll start there really with a rich round of thanks.
- 3:01With respect to the study, patients who have trigeminal neuralgia and continue to have pain,
- 3:08both the frequency of paroxysms and pain associated with them,
- 3:13as well as chronic or continuous pain, are invited into the study.
- 3:18Of course, if they achieve the screening procedures and are able to move into the trial itself,
- 3:25are always assured some exposure to the investigational medicine,
- 3:30which we know is important to patients with trigeminal neuralgia.
- 3:34So that's why we're conducting a design study called a randomized withdrawal
- 3:40study, with which I think you're very familiar.
- 3:44Patients first come in, and then everybody gets a chance to be exposed to this
- 3:50investigational medicine, NOE 101.
- 3:53If patients respond positively to it, and in the study that means have a 30%
- 3:59or better improvement in their pain,
- 4:02then they can enter the blinded portion of the trial, in which they will be
- 4:06switched to either placebo or to active medication.
- 4:10We try to minimize the time on placebo, and patients are certainly available
- 4:15to take additional medications as rescue in case they do have problems during that placebo period.
- 4:23I think we all recognize that some comparison to placebo in the development
- 4:27of a medication is critical to allow the FDA and other regulators understand
- 4:32its potential benefit and safety for patients.
- 4:36So in the trial, then, patients move into a double-blind portion of the study and continue on.
- 4:43Once they complete that study, which is a total of 12 weeks.
- 4:48Patients can achieve and gain then further access to the NOE 101 medication
- 4:53for an additional year following that double blind portion.
- 4:57So in total, patients could have access to medication for roughly about a year
- 5:03and a half if it is the medication that they find effective as well as tolerated and safe.
- 5:10So in general, that is the research platform.
- 5:14Folks come in, get screened, get exposed to the drug, and then if they do have
- 5:18a good response, move on to a blinded portion.
- 5:22Whatever they happen to be on, though, they still get access to NOE 101 following
- 5:27that portion of the study should they choose to continue.
- 5:30We found all of that has made, I'd say a few things.
- 5:34One, we have a lot of folks who are continuing on into that open label extension
- 5:37at this point. So certainly we've gotten impressions from sites and from patients
- 5:43that they're tolerating the medication well and finding it of import and utility for their pain.
- 5:49So I'm not going to go into further depth because I have some great colleagues
- 5:53who can talk about the details of the study, what kind of patients might enter,
- 5:58how you can go about entering.
- 6:00And I'll leave some of those details for my colleagues next.
- 6:04Thank you so much, Dr. Lasser. That was really helpful information.
- 6:07And I know you answered several questions that I've kind of seen in our community
- 6:11regarding how the medication is given during the trial. So thank you so much for addressing those.
- 6:18Amin, I've had the pleasure of working with you over the last four years to support this study.
- 6:23Can you share your unique insights on where the trial started and where you hope it is headed?
- 6:30Yes, kindly. It was my pleasure to work with the Facial Pain Association during these four years.
- 6:37As you know, developing a new therapy is a long journey and requires the help
- 6:42of and support of patients.
- 6:45The LIBRA study was designed with the insights of patients' representatives,
- 6:50and this is why, for example, we included one year of open-label extension where
- 6:54patients get access to the BRCA, as I've explained before.
- 6:58The clinical study, as we speak,
- 7:00is ongoing, and patients from several countries in Europe and in the U.S.
- 7:05Joined the study. We plan to complete this study by the end of 2025 and then delete the data.
- 7:11This will help us to understand the drug efficacy and safety in reducing the
- 7:16pain, which is due to tergibial neuralgia.
- 7:19Thank you so much, Amin. I appreciate you sharing that.
- 7:22And, you know, it has been our honor as well to work with Neema over the last
- 7:28four years and really consider our relationship a model and how,
- 7:33you know, those who are investigating drugs can partner with patient organizations
- 7:38to really address needs that our community has. So thank you so much.
- 7:43Rob, on that note, I know you've spent a lot of time connecting with people
- 7:47living with facial pain at the Facial Pain Association support group meetings.
- 7:51How has the patient voice, as well as feedback about the trial, helped shape the trial?
- 7:59Thank you, Brandy. We are obviously very grateful for the collaboration with FPA.
- 8:05And as Amin mentioned, we have already taken several individual feedbacks and
- 8:11incorporated that into the program.
- 8:12Of course, patients' experiences with their conditions are always a key feature
- 8:17of any clinical trial planning because one of the goals of a drug development
- 8:21is, beyond trying to understand if a drug is safe and efficacious,
- 8:26is also to address difficult and pervasive symptoms that impact patients' quality
- 8:30of life and satisfaction with the treatment.
- 8:34And nowhere is that more evident than with TGN.
- 8:37We've now had, as you alluded to, several opportunities to reach out and directly
- 8:43speak to patients about their concerns.
- 8:45And the reality is that outcomes for this condition need to be more than just
- 8:51severity and frequency of attacks, as important as those are to understanding
- 8:55how a potential drug works.
- 8:57We've heard time and again with FPA, by engaging with FPA patients,
- 9:00that there is a real narrowing of patients' lives that occurs throughout the
- 9:05course of the illness that results in a substantial loss of life activities for these patients.
- 9:11And this is something that we've heard loud and clear and that we're exploring
- 9:15in an effort to more clearly define for patients and for everyone,
- 9:19really, what treatment success looks like and address truly unmet needs from
- 9:24the patient's perspective.
- 9:27Thank you so much, Rob. And thank you for the time you have given to speak with
- 9:32patients, to understand their experiences, to hear their life stories.
- 9:36It has been very impactful for our community as well to be able to share that
- 9:40with professionals and researchers who genuinely care. So thank you so much.
- 9:46And Denise, can you walk us through how someone with facial pain can get involved in the study?
- 9:52And if they do join the trial, what can they expect?
- 9:56Sure, absolutely. And thanks again, Brandy, for having us here.
- 9:59I will echo what my colleagues have said, too.
- 10:01It's been amazing partnering with you and the FPA for all these years so far
- 10:06and continued collaboration, we hope, as well.
- 10:09So right now in the U.S., we've got four sites.
- 10:13One is in La Jolla, California. One's in New York City. One's in Cincinnati,
- 10:17Ohio, and the other is in Tampa, Florida.
- 10:20The contact information for all of these sites is actually located on the FPA website.
- 10:26And if you go to the website and then click resources and scroll to research,
- 10:33you scroll down the page, excuse me, you scroll down the page and look for the
- 10:38Libra study, which is actually on the left hand side of the corner.
- 10:42Yes, I've done this a couple of times.
- 10:44And then when you click on that, you can read very thorough information about what the study entails.
- 10:50And I'll go through that in a moment. But the contacts for all the sites,
- 10:54if you scroll almost all the way to the bottom, is located there.
- 10:58There's names of the study coordinators and their contact, email and phone number.
- 11:02So you can reach out to the site that is closest to you.
- 11:05If you do need to travel, NOEMA will cover the travel costs if you're eligible for the study.
- 11:10And that's something that the site will go through with you.
- 11:12And we have a vendor that will help you with planning your travel and covering all the costs.
- 11:19So you should have very little out of pocket expense if you need to travel.
- 11:24And that is, again, is something that you'll speak with the site about what makes sense for you.
- 11:28Once you call the site, or they call you, depending on how you're interacting,
- 11:33they will do a pre-screening.
- 11:34Once that's complete, if they feel that from the general questions they ask
- 11:39that you could potentially be eligible, you'll be brought in for an in-clinic
- 11:42visit with the study physician and study team.
- 11:45You'll go through several questionnaires. They'll do some blood work,
- 11:49ECG, want to make sure that you're healthy as well before entering the study.
- 11:53If you're deemed eligible after that, you'll be asked to come back probably
- 11:57about 10 days later for your what is called a baseline visit.
- 12:01And at that point, you will be given your medication for the study.
- 12:05During those visits, you'll be asked questions about your pain and other definitions
- 12:10of, or excuse me, other conditions that may be there, concomitant meds, etc.
- 12:14If you're currently on a medication, the study doctor will talk to you about
- 12:18titrating off that medication onto our study medication, the Zimglurant.
- 12:24You will come back again for a week one visit, and then after that,
- 12:29you won't have to come back to clinic until week eight.
- 12:32So most of the visits are actually remote, and the site will help you set those
- 12:36up and show you how to set up the video conferencing.
- 12:40There is also something very, very important. It's a pain diary that you'll
- 12:44be asked to complete daily.
- 12:47This is incredibly important because this is what helps us determine, as Dr.
- 12:51Lasser said earlier in the podcast, if you have reached that 30% decrease in your paroxysms.
- 12:58If we don't have that data, we can't make that calculation. So it's very important
- 13:02for you to put that in there.
- 13:03And it's a very easy application, and your study coordinator or study physician
- 13:08will teach you how to do that.
- 13:09Excuse me. After week eight, if you are eligible to continue into the next phase,
- 13:15the doctor will explain that this phase is a double blind.
- 13:19So you'll either stay up as a morant or get randomized to placebo. And as Dr.
- 13:24Lasser and I believe Amin mentioned as well, there are steps that the study
- 13:29coordinator and physician will take to ensure that you're safe and comfortable
- 13:33and get you through period two.
- 13:36Those visits, again, are also remote, but there are a couple in-clinic visits as well.
- 13:41And then if you continue after that into the open-label extension, which is what Dr.
- 13:47Lasser had mentioned earlier with a year of the medication, then you will come
- 13:51back in for a few in-clinic visits.
- 13:53And then every three months, phone call, and then towards the end, another in-clinic.
- 13:58So of the complete study, you will have nine in-clinic visits,
- 14:04unless you and your study physician feel that you need to come into clinic rather than a phone call.
- 14:09And your study team will walk you through all of this. I know this is a lot
- 14:13of information, but once you do enroll in the study, your study team will also
- 14:17give you this information in a written format.
- 14:21So you're able to go back and look and review and and you'll also have a copy
- 14:26of your informed consent which is completed at screening that explains all of this as well.
- 14:31Thank you, Denise. That was really helpful information, very detailed.
- 14:35And also, thank you for walking through where people listening today can find
- 14:40the information on FPA's website.
- 14:43It's also available on clinicaltrials.gov.
- 14:46I believe you also mentioned that as well, Denise. Thank you. Absolutely.
- 14:50And just very quickly, grab a pen.
- 14:53The clinicaltrials.gov number is N-C-T-05-2-1-7-6-2-8.
- 15:06But the good news is that's also listed on the FPA website in case you missed it. So thank you.
- 15:13Excellent. Thank you for providing that, Denise. That's super helpful.
- 15:16Let's shift gears. Dr. Lasser, Rob, Amin, Denise, as we wrap up,
- 15:21could each of you share one key takeaway about this trial?
- 15:27I'll start from the NOEMA side. We think the trial, I'll use two words,
- 15:33are about hope and collaboration.
- 15:36There's no way that companies can provide the kind of new medications and new
- 15:42supports for people unless folks are willing to step forward.
- 15:46And the fact that so many have already stepped forward gives us such great confidence
- 15:52in being able to achieve our goals,
- 15:54which in the end is a shared goal, to be able to find new medicines and new
- 15:59research for patients with trigeminal neuralgia.
- 16:02So really hope and that collaboration or partnership.
- 16:06To complement what Rob said, I would like to add that the study is ongoing.
- 16:11I would like to thank the participants and the patients who are supporting this
- 16:16development by providing insights to the way to design the trial and who are
- 16:22participating to the study.
- 16:23And you can still join. Brandy and Denise sharing with you a lot of details
- 16:28how the study is designed, what are the procedures and where you can find more
- 16:33information and connect with the doctors who are participating for the study.
- 16:38So the study is ongoing. Thank you.
- 16:41So from my perspective, what struck me about this trial and this program is
- 16:45that it's fairly unique.
- 16:48There are many programs for pain, but when you think about trigeminal neuralgia
- 16:54and the chronicity of the disease and the uniqueness of how the disease impacts patients,
- 17:00you see that this study is quite unique because there are not only a very limited
- 17:05number of effective treatment options,
- 17:07there are a few that are being developed as we speak.
- 17:09So this is one of the few programs, and not only now, but across the history
- 17:14of pain research that is focused on these patients.
- 17:19And we're really proud of that. And the takeaway is that it's a very important
- 17:25trial in the landscape of trials.
- 17:30Great. And then I will take a different perspective since I feel that our esteemed
- 17:35colleagues have spoken scientifically.
- 17:37I want to talk a little bit more about my thought on participating.
- 17:41So one thing I can say is be patient with the process.
- 17:45We understand folks with this condition have suffered for years and only those
- 17:52who share that suffering can understand.
- 17:54So we don't pretend to understand what you're going through,
- 17:58but we are here to try to change that for your future.
- 18:02And we also understand, I know Rob Silva mentioned earlier, when talking with
- 18:07the folks, we know that the anticipation of having the pain is almost sometimes
- 18:13greater than the pain itself.
- 18:14And so one of the things I want to really, really reinforce is that your study
- 18:20teams will work very closely to transition you into a study,
- 18:24which is probably a different experience as well, regardless of your condition.
- 18:29And as you transition, that team will work with you to ensure a safe and tolerable process.
- 18:35So again, we understand that it's going to be probably a little scary,
- 18:39but please know that the team is there to support you all the way through.
- 18:44And finally, one thing, give it a chance.
- 18:47When you get in study, ask the questions. If you're scared, if you're nervous,
- 18:51if your anticipation of pain is bothering you, let your study team know.
- 18:56They have ways to help you work through it. Thank you.
- 19:00Very well said. And I think hope really does capture what research and what
- 19:05this study can provide to the facial pain community.
- 19:07And thank you so much, Dr. Lasser, Amin, Rob, and Denise for sharing your insights.
- 19:13It's really inspiring to see how research like this can not only advance potential
- 19:18treatments, but also prioritize patient needs.
- 19:22Today, we've only scratched the surface. For more information about the Libra
- 19:26study, visit clinicaltrials.gov or the Facial Pain Association's website at facepain.org.
- 19:33For a deeper dive into the study, I encourage you to watch the full webinar,
- 19:37which includes a Q&A session with audience questions answered by the experts
- 19:43who joined us here today.
- 19:44Visit facepain.org to watch the recording and explore other valuable resources.
- 19:50Until next time, I'm sending you best wishes for pain-free days.
- 19:55Music.